Welcoming a new age of precision neuroscience

NR Times reports on how the pioneering work of Aprinoia Therapeutics could influence better patient outcomes in neuro-rehab; in conversation with chief medical officer Bradford Navia.

‘Precision neuroscience’ is a term which encapsulates the ceaseless drive for more targeted and effective brain treatments and diagnoses.

Not to be confused with Elon Musk’s neuro-tech startup of the same name, it sits at the intersect between two emergent health innovation trends; the rise of precision medicine – tailored interventions that consider genes, environments and lifestyles – and an acceleration of our understanding of the neurological world.

On the frontline of the precision neuroscience movement is Aprinoia, a clinical-stage biotech headquartered in Boston which is opening up new possibilities for the diagnosis and treatment of neuro conditions including Alzheimer’s and Parkinson’s.